Last reviewed · How we verify
Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers
Hypertension and hyperuricaemia are widespread conditions. There is significant overlap between the two conditions. Serum uric acid (SUA) is currently recognized as a risk factor for cardiovascular disease. Thus, at some point in their therapy, hypertensive patients with hyperuricaemia are likely to require concurrent treatment with anti-hypertensive and hypouricaemic agents. For this reason, it is important to determine whether there are any pharmacokinetic interactions resulting from the concomitant administration of such agents.Olmesartan is an angiotensin II receptor antagonist and effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricaemic agent for the treatment of hyperuricaemia and gout.The goal of this study was to examine the impact of coadministration of probenecid on the pharmacokinetic parameters and tolerability of olmesartan in healthy volunteers.
Details
| Lead sponsor | Central South University |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | 2009-08 |
| Completion | 2009-10 |
Conditions
- Drug Interaction of Olmesartan in Healthy Chinese Volunteers
Interventions
- olmesartan medoxomil
- olmesartan medoxomil+probenecid
Primary outcomes
- pharmacokinetic parameters — 48 hours after last administration of olmesartan medoxomil
pharmacokinetic parameters:AUC0-48, AUC0→∞ and Css-av , tmax, t1/2, Css-max, and Css-min
Countries
China